Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 39 briefings matching “kidney”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

GASTROENTEROLOGY · REAL-WORLD COHORT

Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study

Unlocking the Genetic Link Between Liver Failure and Kidney Damage. Scientists have pinpointed a specific gene, SUSD1, that significantly increases the risk of kidney problems in people with severe liver disease.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 15, 2026

NEPHROLOGY · PRECLINICAL

Gut-targeted interventions to complement PTH-lowering therapy

These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health. Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · PHASE I/II

Fingerprinting the polycystic kidney: radiomics of the noncystic parenchyma for earlier ADPKD detection

Small, cross-sectional, unmatched data require longitudinal validation of reproducibility, prognostic value, and clinical utility. Autosomal dominant polycystic kidney disease risk stratification relies on total kidney volume, a validated marker of cyst burden and progression.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · CLINICAL PRACTICE

Kidney stone disease: to drink or not to drink-that is the question

Effective prevention likely requires achieving a substantial increase in urine volume alongside comprehensive dietary and pharmacologic management. An important point to note is that these findings do not invalidate the protective role of increased urine volume but highlight the limitations of behavioral interventions alone.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · CLINICAL PRACTICE

The macrophage paradox in renal AL amyloidosis: lessons from histology and imaging

These findings offer insights into the mechanisms of renal involvement and highlight the complex, context-dependent role of macrophages in amyloid clearance and tissue injury. In renal amyloid light chain amyloidosis, sustained and deep hematologic response drives organ response that continues to improve over time.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · REAL-WORLD COHORT

Estimating GFR: what it is, what it is not, and why prediction cannot settle the question

Equations are population tools; at the bedside, non-glomerular filtration rate determinants of both creatinine and cystatin C can mislead. Schultheiss et al. show that replacing Chronic Kidney Disease Epidemiology Collaboration with European Kidney Function Consortium cystatin C-based equations reclassifies women, but not men, into milder chronic kidney disease stages, while outcome prediction is unchanged.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · REAL-WORLD COHORT

Fetal growth restriction and lifelong risk of acute kidney injury: advancing the developmental origins of kidney disease

We examine the study's strengths, limitations, biological basis, and clinical relevance, highlighting opportunities for targeted risk stratification, preventive care, and future research. Fetal growth restriction has long been associated with reduced nephron number and chronic kidney disease, but its relationship with acute kidney injury has remained unclear.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 15, 2026

NEPHROLOGY · REAL-WORLD COHORT

Applicability of Prediction Models: Aligning Models with Clinical Use

This review offers practical steps to keep predictions aligned with the patients they serve. Using severe chronic kidney disease as an example, this review shows that a model built from patients who have recently progressed to this more severe stage works better for patients at that same point, while a model built from patients who have lived with the disease for years works better for those further along.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 12, 2026

NEPHROLOGY · REAL-WORLD COHORT

Pooled cohort analysis of renin-angiotensin system inhibition and the risk of kidney outcomes in APOL1-mediated chronic kidney disease in the CRIC and SPRINT studies

RASi-based therapy, addressed as a time-updated pooled treatment, provided similar benefit across APOL1 genotypes, driven by albuminuric participants. Among individuals with two APOL1 risk alleles, outcomes were similar regardless of baseline albuminuria.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readKidney InternationalNov 12, 2026

IMMUNOLOGY · PRECLINICAL

Granzyme K is a driver of age-related tissue remodeling and functional decline independently of age-associated immune dysfunction

These findings identify GzmK as a tissue-specific driver of organismal aging but not immune aging or systemic inflammaging. In the kidney, this was associated with reduced complement deposition, whereas in the liver, improved function and reduced fibrosis (tissue scarring) occurred independently of complement, coinciding instead with increased decorin and reduced pro-fibrotic TGF-β signaling.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readImmunityNov 12, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo (inactive comparison treatment), highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and risk of death in this high-risk population. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMA CardiologyNov 11, 2026

NEPHROLOGY · PRECLINICAL

Metabolic Unloading: How SGLT2i Recalibrate Cell Energetics to Slow CKD Progression

This review positions cellular energetics as an important upstream constraint shaping kidney disease progression, offering a foundation for nephroprotective strategies. This framework integrates spatial cortex-medulla vulnerability, reconciles early hemodynamic changes with durable slowing of estimated glomerular filtration rate decline, and explores disease-agnostic benefit.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readKidney InternationalNov 11, 2026

Showing 12 of 39 medical briefings

Interactive Fact Check